All Cancer articles
-
NewsWhole-genome sequencing delivers actionable biomarkers in 73 percent of cancer patients
A large real-world study published in Nature Medicine demonstrates that whole-genome sequencing can identify actionable biomarkers in nearly three-quarters of solid cancer patients within routine clinical practice, with findings that carry significant implications for precision drug development and biomarker-driven treatment strategies.
-
NewsPatient-derived tumour organoid biobank maps cancer gene dependencies
A biobank of 256 patient-derived tumour organoids, combined with genome-wide CRISPR–Cas9 screening, has produced a detailed map of cancer gene dependencies across five tumour types, revealing both shared vulnerabilities and mutation-specific targets with implications for precision oncology.
-
NewsNew LOX target discovery could help overcome chemotherapy-resistant breast cancer
A preclinical study has identified lysyl oxidase as an intracellular survival factor in triple-negative breast cancer, with researchers demonstrating that sequentially blocking LOX and a compensatory ferroptosis defence pathway significantly suppresses tumour growth without chemotherapy.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
-
NewsReview challenges one-size-fits-all approach to OSCC drug delivery
A new review published in the European Journal of Pharmaceutics and Biopharmaceutics argues that no single local drug-delivery formulation will suit every oral squamous cell carcinoma tumour, urging researchers to anchor development in clinical and biological context from the outset.
-
NewsBRAF identified as novel target for neuropathic pain treatment
Researchers at MD Anderson Cancer Center have discovered that BRAF, a protein well known for its role in cancer, may also drive chronic pain following nerve injury – raising the prospect of repurposing approved cancer drugs as treatments for neuropathic pain.
-
NewsHER3-DXd and olaparib combination boosts lung cancer treatment responses
A new preclinical study finds that combining the antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib significantly improves treatment responses in NSCLC models, including those harbouring EGFR and KRAS mutations, by overwhelming DNA repair capacity and activating innate immune signalling.
-
NewsFirst-in-class drug targets ‘undruggable’ MYC in blood cancers
A first-in-class experimental drug has demonstrated preclinical activity against treatment-resistant blood cancers by exploiting a newly identified vulnerability between MYC and GSPT1, offering a potential route to one of oncology’s most elusive targets.
-
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
-
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
-
NewsExhausted T cells escape tumours to drive lasting cancer immunity
A preclinical study has identified a subset of exhausted, LAG3-expressing T cells capable of migrating out of tumours to establish long-term immune memory, with potential implications for LAG3-targeting cancer immunotherapies.
-
NewsNUS researchers identify molecular switch driving TNBC treatment resistance
Researchers at the National University of Singapore have identified DP103 as a potential molecular master switch sustaining tumour growth, cancer stem cells and treatment resistance in triple-negative breast cancer, with findings suggesting it could serve as a predictive biomarker for the investigational oral therapy RX-5902.
-
NewsPatient-specific brain tumour chip models vascular drug barriers
A microfluidic chip combining patient-derived glioblastoma cells with their tumour vascular environment could give drug developers a more realistic preclinical model for predicting treatment response – and may help explain why genetically similar patients respond differently to the same therapy.
-
NewsAGR2 and FOXM1 identified as prognostic and therapeutic targets in NF-PanNETs
A new study using single-cell RNA sequencing has identified AGR2 as a potential prognostic marker and FOXM1 as a druggable target in non-functional pancreatic neuroendocrine tumours, offering new tools to stratify patients and guide treatment strategies.
-
NewsMulti-target screening refines ADC development for cervical cancer
A large-scale transcriptomic study has pinpointed distinct cell-surface targets for antibody-drug conjugate development across cervical cancer subtypes, revealing how tissue-of-origin comparisons and subpopulation analysis can uncover targets missed by conventional screening approaches.
-
NewsNanomedicine for glioblastoma: overcoming the blood-brain barrier
A new review published in Chinese Neurosurgical Journal examines how nanoscale drug delivery systems could help overcome one of the most persistent obstacles in glioblastoma treatment – getting therapeutics across the blood–brain barrier and into tumour tissue.
-
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.
-
NewsHow CAR T cells are being engineered to target tumour’s ‘soft spot’
A preclinical study published in Nature Biomedical Engineering describes a synthetic biology approach that converts the physical softness of cancer cells into a targetable signal for CAR-T immunotherapy, potentially addressing a key resistance mechanism in solid tumours.
-
NewsAI identifies experimental drug targeting undruggable cancer protein
Mayo Clinic researchers have used AI to screen nearly 40,000 compounds and identify a small molecule inhibitor targeting GIPC1, a protein previously considered undruggable, with preclinical results showing slowed tumour growth and enhanced chemotherapy response.
-
NewsTargeting the roots of head and neck cancer: Why MDA-9 matters
A small molecule inhibitor developed at Virginia Commonwealth University has demonstrated the ability to eliminate cancer stem cells and reverse cisplatin resistance in preclinical models of head and neck squamous cell carcinoma, offering a potential new strategy to address one of oncology’s most persistent clinical challenges.